← Leaderboards
Danielle A Garsin
University Of Texas Hlth Sci Ctr Houston
$10,870,643
Attributed
$14,575,300
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,575,300 · 12
By mechanism
R01$11,956,807 · 5
R21$1,497,671 · 4
R56$830,152 · 2
T32$290,670 · 1
Top collaborators
- Michael C Lorenz11 shared
- Wade Winkler7 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Michael C Lorenz$12,581,222
- Ambro Van Hoof$7,129,078
- Hitesh Kapadia$661,403
- Nami McCarty$4,379,218
- Todd A Cameron$124,284
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationGenesPreventSourcePathogenInfectionMutantCaenorhabditis ElegansResponsePublic HealthProteinsEnterococcus FaecalisBaseCellsAntimicrobialAffectIntestinesPathway InteractionsRegulationInvestigationBiologyCommunicable DiseasesIn VitroAnimals
Grant awards (42)
Mechanism of Fungal Virulence Inhibition by a Bacterial Peptide$713,142
R01 · FY2025 · AI
Elucidating the parameters of intracellular ethanolamine utilization$226,980
R21 · FY2025 · AI · contact PI
Genetic approaches to probe virulence and drug resistance in Candida auris$191,279
R21 · FY2025 · AI
Mechanism of Fungal Virulence Inhibition by a Bacterial Peptide$727,142
R01 · FY2024 · AI
Response to Immune Associated Stress$478,931
R01 · FY2024 · AI · contact PI
Genetic approaches to probe virulence and drug resistance in Candida auris$230,279
R21 · FY2024 · AI
Response to Immune Associated Stress$85,330
R01 · FY2024 · AI · contact PI
Response to Immune Associated Stress$478,931
R01 · FY2023 · AI · contact PI
Texas Medical Center Training Program in Antimicrobial Resistance$290,670
T32 · FY2023 · AI · contact PI
Response To Immune Associated Stress$85,330
R01 · FY2023 · AI · contact PI
Response to Immune Associated Stress$478,931
R01 · FY2022 · AI · contact PI
Inhibition of Candida virulence and biofilm formation by a bacterial peptide$465,335
R01 · FY2022 · DE
Ethanolamine utilizing bacterial microcompartments in host cells$234,000
R21 · FY2022 · AI · contact PI
Inhibition of Candida virulence and biofilm formation by a bacterial peptide$75,955
R01 · FY2022 · DE
Inhibition of Candida virulence and biofilm formation by a bacterial peptide$545,991
R01 · FY2021 · DE
Response to Immune Associated Stress$478,931
R01 · FY2021 · AI · contact PI
Ethanolamine utilizing bacterial microcompartments in host cells$195,000
R21 · FY2021 · AI · contact PI
Inhibition of Candida Virulence and Biofilm Formation by a Bacterial Peptide$31,582
R01 · FY2021 · DE
Response to Immune Associated Stress$475,861
R01 · FY2020 · AI · contact PI
Inhibition of Candida virulence and biofilm formation by a bacterial peptide$470,036
R01 · FY2020 · DE
Inhibition of Candida virulence and biofilm formation by a bacterial peptide$470,036
R01 · FY2019 · DE
Post-initiation regulatory mechanisms controlling ethanolamine utilization$456,020
R01 · FY2019 · AI · contact PI
The role of reactive oxygen species in mucosal innate immunity$342,305
R01 · FY2019 · AI · contact PI
Inhibition of Candida virulence and biofilm formation by a bacterial peptide$470,036
R01 · FY2018 · DE
Post-initiation regulatory mechanisms controlling ethanolamine utilization$456,020
R01 · FY2018 · AI · contact PI
The role of reactive oxygen species in mucosal innate immunity$342,305
R01 · FY2018 · AI · contact PI
Post-initiation regulatory mechanisms controlling ethanolamine utilization$456,020
R01 · FY2017 · AI · contact PI
The role of reactive oxygen species in mucosal innate immunity$342,305
R01 · FY2017 · AI · contact PI
The role of reactive oxygen species in mucosal innate immunity$81,614
R01 · FY2017 · AI · contact PI
Post-initiation regulatory mechanisms controlling ethanolamine utilization$456,020
R01 · FY2016 · AI · contact PI
The role of reactive oxygen species in mucosal innate immunity$342,305
R01 · FY2016 · AI · contact PI
Post-initiation regulatory mechanisms controlling ethanolamine utilization$364,270
R01 · FY2015 · AI · contact PI
The role of reactive oxygen species in mucosal innate immunity$171,153
R01 · FY2015 · AI · contact PI
Post-initiation regulatory mechanisms controlling ethanolamine utilization$431,000
R56 · FY2014 · AI · contact PI
The Role of Reactive Oxygen Species in Mucosal Innate Immunity$309,099
R01 · FY2013 · AI · contact PI
The Role of Reactive Oxygen Species in Mucosal Innate Immunity$328,885
R01 · FY2012 · AI · contact PI
Mechanism of Gene Regulation by RNA-Binding ANTAR Proteins$399,152
R56 · FY2011 · AI · contact PI
The Role of Reactive Oxygen Species in Mucosal Innate Immunity$328,941
R01 · FY2011 · AI · contact PI
The Role of Reactive Oxygen Species in Mucosal Innate Immunity$332,318
R01 · FY2010 · AI · contact PI
The Role of Reactive Oxygen Species in Mucosal Innate Immunity$315,727
R01 · FY2009 · AI · contact PI
Regulation of Ethanolamine Utilization in E. Faecalis by an Atypical Riboswitch$184,812
R21 · FY2009 · AI · contact PI
Regulation of Ethanolamine Utilization in E. Faecalis by an Atypical Riboswitch$235,321
R21 · FY2008 · AI · contact PI